. This metabolic disruption results in increased bone destruction (osteolysis). increased bone formation (osteosclerosis) or both (Paterson. 1987 : Carter. 1985 . Osteolytic metastases are the predominant type of bone lesions in most cancers. whereas a sclerotic appearance is seen in the majority of metastases from prostatic cancer (PC). in about 10% of metastases from breast cancer (BC) and even more rarely in those derived from other cancers (Stoll, 1983 
Metastatic tumours in the bone interfere with normal bone remodelling by the local release of cytokines and growth factors that increase osteoclast and or osteoblast activitv (Mundy, 1991) . This metabolic disruption results in increased bone destruction (osteolysis). increased bone formation (osteosclerosis) or both (Paterson. 1987 : Carter. 1985 . Osteolytic metastases are the predominant type of bone lesions in most cancers. whereas a sclerotic appearance is seen in the majority of metastases from prostatic cancer (PC) . in about 10% of metastases from breast cancer (BC) and even more rarely in those derived from other cancers (Stoll, 1983) .
Assessment of metastatic disease in the skeleton has been and remains a difficult issue. Metabolic interactions between tumour and bone cells are relatively neglected. Information from the imaging techniques (lytic, mixed or blastic appearances at radiograph or computerised tomography. hotspots at isotope scan) refers to focal lesions and relevant morbiditv.
Efforts to achieve a biochemical assessment of tumour activity are needed (Coleman. 1994) . As the actual production of paracrine agents involved in bone remodelling cannot be directly estimated. a suitable approach is offered by evaluating the consequent changes in rates of bone formation and resorption by means of bone turnover markers (Coleman et al.. 1988) .
A number of indicators are of value when exploring different aspects of bone cell function. Among those of bone formation. bone-specific alkaline phosphatase (BALP) can now be measured in blood more easily than in the past. BALP is present on the surface of osteoblasts. but the mechanism of its release in the circulation still remains unclear (Azria. 1989 In all 102 patients were diagnosed as having lytic lesions, 38 mixed and 34 blastic. Overall 80 patients were found to have more than three sites involved and 94 fewer than or equal to three.
Marker assays All samples were drawn or collected in the early morning after an overnight fast and included spot urine specimens for determination of calcium and creatinine and blood specimens for assessment of calcium, creatinine, albumin, BALP, PICP, BGP and ICTP. Urine collection was performed as follows: the patients were maintained on an unrestricted diet; after a 10 h overnight fast, they emptied their bladders and the urine was discarded. All subjects then drank 250-500 ml of deionised water, after 1 h a second urine sample was collected in a plastic container. Serum and urine samples were stored at -70°C until analysis. Serum PICP, ICTP and BGP were measured in duplicate using commercially available radioimmunoassay (RIA) kits (Farmos Diagnostica, Ounsalo, Finland and CIS Diagnostici, Santhia, Italy). The intra-and inter-assay coefficients of variation were 4.2%, 4.5%, 4.3% and 5.5%, 6.8%, 7.0%, respectively, between 20% and 80% displacement values. Serum alkaline phosphatase (ALP) was measured with a well-standardised kinetic colour test (Merck Diagnostica, Darmstadt, Germany) using p-nitrophenylphosphate as a substrate; the coefficients of variation were always below 5% in a whole range of values. BALP was performed using electrophoretic separation. Serum calcium (CaS) and creatinine measurements were made with standard autoanalyser techniques. Calcium concentration was corrected to a reference serum albumin of 40 g L`using a correction factor of 0.02 mmol g-' albumin. Urinary excretion of calcium was expressed as molar ratio of calcium to creatinine (CaCr, mmol mmol-'). Serum PTH concentration (intact molecule) (RIA kit, Nichols San Juan Capistrano; intra-and inter-assay variations of 4.0 and 5.8) was also evaluated in the early morning. (Figure 1 ).
Markers of bone turnover and extension of disease Patients with lytic metastases and more than three bone sites involved had medians of all markers higher than those with a lower number. Only ICTP, BALP and PICP, however, attained statistical significance (Table V) . As far as patients with mixed and blastic lesions were concerned (Table V) , the levels of either bone formation or collagen resorption markers had an apparent tendency towards higher values in the group with more extensive skeletal involvement but the differences did not attain statistical significance except for ICTP in patients with mixed lesions (P<0.01). CaCr and PTH did not show appreciable changes as a function of the extension of disease in patients with lytic and mixed lesions. (Steward and Broadus. 1990 ) and or tumour-derived cytokines or prostaglandins. independently of the presence of tumour cells in bone (Paterson et al.. 1991) . We believe, in any case. that bone involvement should be taken into account as well as the contribution to serum ICTP of non-skeletal involved tissues (skin in particular) (Meikko et al.. 1990) .
With regard to bone formation markers. they were above the reference value in a small number of patients without bone appearances and in about one out of three of those with lytic appearances. As no patient in these groups was found to have elevated bone formation markers without concomitantly elevated bone resorption markers. it seems that raised osteoblast function reflects the maintenance of the coupling processes. although inadequate. to counteract effectively the mechanisms responsible for bone loss.
Indices of bone synthesis increased significantly in patients with lytic compared with those with mixed and blastic appearances. but a somewhat unexpected finding was the 1586 absence of a consensual ICTP reduction. The discrepancies between markers of osteoblast and osteoclast activities have been confirmed analysing the patient subset with disease apparently confined to the skeleton. Our data may be viewed as consistent with previous reports of histomorphometric evidence of bone resorption besides synthesis in apparently pure blastic lesions (Clarke et al., 1991) . When considering albumin-corrected serum calcium concentrations, subclinical hypercalcaemia in bone metastatic patients is more frequent than previously thought, but hypocalcaemia is also not so rare (Mundy, 1990; Riancho et al., 1989) . In the present series, 16% of patients had calcium levels higher than normal (12% of them with clinical signs of hypercalcaemia), whereas 4.6% had lower than normal levels yet were asymptomatic. Hypercalcaemia was more frequent in patients with lytic and mixed lesions. Serum PTH showed an opposite pattern -values below the detection limits were more frequently observed in patients with lytic lesions and supranormal levels in those with blastic appearances.
PTH stimulation of osteoclast activity could be a factor accounting for the higher resorption rate observed in a number of these latter patients. Correlations between markers were sought in distinct populations of patients: those with lytic lesions and those with mixed and blastic lesions. Significant correlations were found between BALP and PICP, but not BGP, in patients with lytic appearances, and between BALP and BGP, but not PICP, in patients with mixed/blastic ones. The reasons for these disrepancies are unclear. The control of osteoblast activity is multifactorial even in the absence of bone involvement from neoplastic cells. Serum markers of bone synthesis may also display divergent patterns in patients bearing non-malignant disorders of bone turnover, such as acromegaly and Paget's disease (Hosking, 1990; Terzolo et al., 1993) .
In patients with mixed/blastic lesions the inverse relationship between serum PTH and serum calcium values and the parallelism between serum PTH and BALP suggest that a secondary hyperparathyroidism may exist owing to calcium entrapment in the bone. In these cases, the direct relationship between PTH and ICTP could reflect the PTH effect on bone collagen breakdown of tumour-free bone tissue (Rico et al., 1990) . Hyperparathyroidism (Rico et al., 1990 ) and hypophosphataemia (Jacobs, 1983) have been described previously in prostatic cancer patients with bone metastases. This metabolic picture, called bone hunger syndrome (Rico et al., 1990) , may result in increased resorption and osteomalacia in bone sites distant from tumour metastases (Urwin et al., 1985) and could contribute to morbidity.
The procedure used by us to assess tumour extent refers only to the number of sites involved and does not take into account the percentage of bone involvement within each site. Nevertheless, in all subgroups a more pronounced elevation of marker levels was found in patients with more than three metastatic sites when compared with those with less bone involvement. Only one exception should be noted in the general tendency of biochemical indices to parallel the tumour extent. In patients with blastic lesions CaCr diminished together with serum calcium, while increasing both the tumour load and ICTP levels. This observation seems to be in line with the postulated PTH increase and with the concept that the pathogenesis of collagen loss in patients with blastic lesions is different from that of patients with lytic lesions.
In conclusion, the mismatch between bone formation and resorption in cancer patients with skeletal involvement varies consistently from patient to patient, according to radiograph appearances, and recognises complex mechanisms. The usefulness of a biochemical assessment of bone metabolism in metastatic patients eligible for antineoplastic treatments remains to be established. The relationship with the appearance extension at radiology augurs well for their employment in follow-up studies.
